Pandion and Astellas Announce Collaboration to Deliver Pancreas-Targeted Immunomodulators
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Business Wire
Exclusive Collaboration Utilizes Pandion’s Platform to Discover Novel Tissue-Specific Immunomodulators for Type 1 Diabetes and Other Autoimmune Diseases of the Pancreas CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Pandion Therapeutics, Inc. (“Pandion”), and Astellas Pharma Inc. (TSE: 4503, "Astellas") announced today the signing of a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191030006210/en/The collaboration will allow the parties to combine Pandion’s modular biologics and functional immunology expertise with Astellas' advanced therapeutics development and global commercialization capabilities for the treatment of autoimmune diseases. Under the terms of the agreement, Pandion will be responsible for design and discovery of bispecific drug candid
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves [Yahoo! Finance]Yahoo! Finance
- Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for ThemselvesPR Newswire
- VEOZAH® (fezolinetant film-coated tablets) Receives Health Canada Approval as First and Only Non-hormonal Treatment for Vasomotor Symptoms (VMS) Associated with Menopause [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- VEOZAH® (fezolinetant film-coated tablets) Receives Health Canada Approval as First and Only Non-hormonal Treatment for Vasomotor Symptoms (VMS) Associated with Menopause [Yahoo! Finance]Yahoo! Finance
- Asia now exports culture, ideas, tech and leadership [Yahoo! Finance]Yahoo! Finance